Stocks Health care NCEL
NASDAQ · Health careNewcelX Ltd. (NCEL)
It posted a net loss of $8.3M. In fiscal 2025 capital spending exceeded operating cash flow by $2.8M. At December 31, 2025 it held $2.2M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on April 29, 2026.
What NewcelX Ltd. does
NewcelX Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NCEL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$8.3M | $2.16 | -$2.8M |
| 2024 | n/a | -$7.2M | $2.43 | -$1.1M |
| 2023 | n/a | -$3.3M | $1.13 | -$3.5M |
| 2022 | n/a | -$16.5M | -$33.52 | n/a |
| 2021 | n/a | -$11.9M | -$39.90 | -$15M |
| 2020 | n/a | -$2.9M | -$16.36 | n/a |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What NewcelX Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 18, 2026Form POS AM filing POS AM
- September 18, 2026
- August 20, 2026Form F-3 filing F-3
- August 3, 2026
- July 31, 2026
- July 15, 2026
- July 8, 2026
- July 1, 2026
- June 30, 2026
- June 15, 2026
Insider trades
What the people running NewcelX Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| April 27, 2026 | Revel MichelCSO and Director, Director, 10% owner | Bought | 54,545 | $150K |
| April 27, 2026 | Samuel OlivierDirector | Bought | 81,818 | $225K |
Who owns NCEL
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| League Jinn Sarl13D, may seek influence with 1 related filers | 25.3% | May 4, 2026 |
| Michel Revel13D, may seek influence | 20.2% | November 14, 2025 |
| Ronald Hafner13D, may seek influence | 13.2% | June 24, 2025 |
| Clover Wolf Capital - Limited Partnership13G, passive with 1 related filers | 7.5% | November 7, 2025 |
| Ronen Twito13D, may seek influence | 6% | November 13, 2025 |
Largest institutional holders
Insiders
2 insiders reported holding 1,039,348 shares in total, about $3.1M at the last price.
| Holder | Shares |
|---|---|
| Revel MichelCSO and Director, Director, 10% owner | 957,530 |
| Samuel OlivierDirector | 81,818 |
Questions about NCEL
What does NewcelX Ltd. do?
NewcelX Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NCEL.
Is NewcelX Ltd. profitable?
No. In fiscal 2025 it reported a net loss of $8.3M.
When did NewcelX Ltd. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on April 29, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the form POS AM filing from September 18, 2026.
Similar companies
Compare NCEL with
Follow NCEL
Get an email when NewcelX Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Follow NCEL: get an email when it filesWhere the numbers come from
Financial figures are the values NewcelX Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.